Virtue Capital Management LLC Purchases New Position in Halozyme Therapeutics, Inc. $HALO

Virtue Capital Management LLC acquired a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the third quarter, HoldingsChannel.com reports. The firm acquired 12,270 shares of the biopharmaceutical company’s stock, valued at approximately $1,355,000.

Other hedge funds also recently added to or reduced their stakes in the company. Sumitomo Mitsui Trust Group Inc. boosted its stake in Halozyme Therapeutics by 4.6% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 11,300 shares of the biopharmaceutical company’s stock valued at $1,248,000 after purchasing an additional 500 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Halozyme Therapeutics in the third quarter worth $640,000. Profund Advisors LLC raised its stake in shares of Halozyme Therapeutics by 4.1% in the third quarter. Profund Advisors LLC now owns 22,633 shares of the biopharmaceutical company’s stock worth $2,499,000 after purchasing an additional 886 shares during the last quarter. Vise Technologies Inc. lifted its holdings in shares of Halozyme Therapeutics by 33.1% during the third quarter. Vise Technologies Inc. now owns 12,645 shares of the biopharmaceutical company’s stock valued at $1,396,000 after purchasing an additional 3,146 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al lifted its holdings in shares of Halozyme Therapeutics by 119.1% during the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 28,700 shares of the biopharmaceutical company’s stock valued at $3,168,000 after purchasing an additional 15,600 shares in the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Price Performance

NASDAQ HALO opened at $130.91 on Monday. The business’s fifty day moving average price is $113.70 and its 200-day moving average price is $83.45. The stock has a market capitalization of $14.86 billion, a price-to-earnings ratio of 39.08, a PEG ratio of 0.49 and a beta of 0.92. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. Halozyme Therapeutics, Inc. has a 1-year low of $61.22 and a 1-year high of $134.00.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. The firm had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. During the same period last year, the business posted $1.54 EPS. The company’s revenue for the quarter was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, equities analysts predict that Halozyme Therapeutics, Inc. will post 8.31 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on HALO. Leerink Partners raised Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $83.00 to $110.00 in a research report on Friday, August 7th. JPMorgan Chase & Co. boosted their target price on Halozyme Therapeutics from $70.00 to $78.00 and gave the stock a “neutral” rating in a research report on Thursday, October 8th. Stifel Nicolaus set a $130.00 target price on shares of Halozyme Therapeutics in a research note on Friday, October 16th. Zacks Research raised shares of Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 13th. Finally, Citizens Jmp lifted their price target on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a research note on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $99.55.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 1,626 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the sale, the director directly owned 40,418 shares in the company, valued at $4,154,970.40. The trade was a 3.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $107.43, for a total value of $2,148,600.00. Following the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $82,482,605.40. This represents a 2.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 125,852 shares of company stock valued at $13,538,046. 2.50% of the stock is owned by company insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.